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NeuronopathicEnzyme replacement therapy (ERT) with exogenous glucocerebrosidase is indicated to treat symptomatic
Gaucher disease (GD), a rare, inherited metabolic disorder. ERT with velaglucerase alfa, which is produced in a
human cell line using gene activation technology, was studied in a 12-month phase III trial in Japanese patients
with type 1 or 3 GD who were switched from imiglucerase ERT (n = 6); the current, open-label, 12-month ex-
tension study was designed to assess longer-term safety and efﬁcacy. Two adult and three pediatric patients
(aged b18 years) were enrolled into the extension study. Every-other-week intravenous infusions were admin-
istered for 63–78weeks at average doses between 51.5 and 60.7 units/kg. Three non-serious adverse eventswere
considered related to velaglucerase alfa treatment, but no patient discontinued from the study. Six serious but
non-drug-related adverse events were reported. No patient tested positive for anti-velaglucerase alfa antibodies.
Hemoglobin concentrations, platelet counts, and liver and spleen volumes (normalized to body weight) in these
patients were generally stable over a cumulative 24-month period from the baseline of the parent trial. The data
suggest that velaglucerase alfa was well tolerated and maintained clinical stability in Japanese GD patients over
2 years after switching from imiglucerase. ClinicalTrials.gov identiﬁer NCT01842841.
© 2016 Shire and the Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Gaucher disease (GD) is an autosomal recessive lysosomal storage
disorder caused by deﬁciency of the glucocerebrosidase enzyme. It is a
rare disease that can occur in any ethnic group. In GD, the glycolipidsw burden; BMD, bone mineral
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lsevier Inc. This is an open access artusually degraded by lysosomal glucocerebrosidase, instead accumulate
in the lysosomes of cells of themononuclear phagocyte system, leading
to the formation of Gaucher cells [1]. Accumulation of these abnormal
cells in various body systems is associated with a range of signs and
symptoms, including hepatosplenomegaly, various bone abnormalities,
thrombocytopenia, anemia, and sometimes neurological abnormalities.
Three clinical subtypes of GD are deﬁned based on appearance and se-
verity of neurological symptoms: type 1 (chronic non-neuronopathic),
type 2 (acute neuronopathic) and type 3 (subacute neuronopathic).
Over 300mutations in the glucocerebrosidase gene have been identiﬁed,
and there appear to be some genotype–phenotype correlations [1]. In
Western European, North American and Ashkenazi Jewish populations,
N370S is the most common mutation and is associated with type 1 GD.
The N370S allele is uncommon in Japan where the L444P allele is the
most prevalent [2]. L444P is associated with more severe disease, and
Japanese GD patients tend to experience an earlier disease onset and
progression with greater neurological involvement [3,4].icle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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GD symptoms, and three ERT products are available, which are adminis-
tered by intravenous infusion. Imiglucerase (Cerezyme®, Genzyme,
Cambridge, MA, USA) is produced by recombinant DNA technology in
Chinese hamster ovary cells and has been in commercial use in Japan
since 1998. Velaglucerase alfa (VPRIV®, Shire, Lexington, MA, USA) is
produced in a human cell line using gene activation technology and
was recently approved in Japan following a 12-month clinical trial in
Japanese patients [5]. Velaglucerase alfa has the same amino acid
sequence as the native human glucocerebrosidase,whereas imiglucerase
differs from the native sequence by a single amino acid. The third
product, taliglucerase alfa (Elelyso®, Pﬁzer Inc., New York, NY, USA) is
a recombinant form of glucocerebrosidase that is produced using plant
cell culture and differs from the native sequence by two amino acids at
the N terminal and up to seven amino acids at the C terminal; to date it
is not available in Japan [6]. Type 1 GD can be managed with oral sub-
strate reduction therapy drugs in those for whom ERT is not an option
and the disease is mild ormoderate (miglustat, Zavesca®, Actelion Phar-
maceuticals, South San Francisco, CA, USA) or in certain adult patients
depending on their cytochrome P450 2D6metabolism status (eliglustat,
Cerdelga®, Genzyme, Cambridge, MA, USA, which is available in Japan).
Velaglucerase alfa has been shown to be efﬁcacious and well-
tolerated in several clinical trials in type 1 GD patients naïve to ERT
[7–10] and in those previously treated with imiglucerase [11–13] for
up to 7 years [14,15]. The ﬁrst clinical trial of velaglucerase alfa dedicat-
ed to Japanese patients with GDwas a 12-month open-label study in six
patients who had previously received imiglucerase, including two pa-
tients with type 3 GD. Velaglucerase alfa treatment was well tolerated
and clinical efﬁcacy variables were maintained [5]. Subsequent to the
parent trial, velaglucerase alfa was approved by the Japanese Ministry
of Health, Labour and Welfare for the improvement of anemia, de-
creased platelet count, abdominal distension due to organomegaly,
and bone problems in patients with GD, including patients with type 3
GD. Here we report the results of a cumulative treatment period of 24
months from patients who were enrolled into the 12-month extension
study, whichwas conducted to assess the longer-term efﬁcacy and safe-
ty of velaglucerase alfa treatment in Japanese patients.
2. Materials and methods
2.1. Study design
This was a multicenter extension study (ClinicalTrials.gov
NCT01842841) to a phase III, 12-month open-label clinical trial
(ClinicalTrials.gov NCT01614574). The results of the parent trial are
detailed elsewhere [5].
The parent trial and extension study were conducted at ﬁve clinical
sites in Japan. The studies were conducted in accordance with ICH Good
Clinical Practice Guidelines and reviewed by the institutional review
boards. Patients gave written informed consent prior to any study-
related procedures. Patients less than 20 years of age gave written
informed consent (and assent where applicable) via a parent or legal
guardian.
The primary objective of the extension study was to assess the
longer-term safety of velaglucerase alfa infusions administered every
other week (EOW) in Japanese GD patients.
Secondary objectives included evaluation of changes in hemoglobin
concentration, platelet count, liver volume, spleen volume, plasma
biomarkers, and bone marrow burden (BMB) scores in all patients,
height and bone age in pediatric patients (aged b18 years), boneminer-
al density (BMD) and markers of bone turnover in adult patients.
2.2. Patients
The parent trial was open to patients aged 2 years or over with a di-
agnosis of GD based on deﬁcient glucocerebrosidase activity inleukocytes (whole blood only) or cultured skin ﬁbroblasts. The trial
was open to patients with either neuronopathic (type 3) or non-
neuronopathic (type 1) GD. Patients switching from imiglucerase treat-
ment and those naïve to ERT alike were eligible for enrollment, but,
ultimately, all patients who were enrolled into the parent trial were
switch patients. In these patients, the following additional criteria
were to be met: 12 or more consecutive months of imiglucerase treat-
ment and a consistent infusion dose between 15 and 60 U/kg during
the 3 months before study enrollment; a hemoglobin concentration
N10 g/dL and a platelet count N100 × 109/L at screening. Exclusion
criteria included the following: a signiﬁcant co-morbiditywith potential
to affect or confound the study results; anemia not related to GD;
hepatitis B or C; recent, worsening bone necrosis; recent, active, and
clinically signiﬁcant spleen infarction; prior splenectomy; history of a
severe infusion-related hypersensitivity reaction to any ERT; pregnancy
and lactation; current treatment with red blood cell growth factor or
chronic systemic corticosteroid use in the preceding 6 months; and
treatment with any investigational drug or device in the 30 days before
informed consent [5].
Patients who completed the parent trial (51 weeks) were eligible to
enroll into the extension study. In both studies, women of child-bearing
potential had to agree to use a medically acceptable method of contra-
ception during study participation.
2.3. Dosing
Velaglucerase alfa was administered EOW (14 ± 3 days) in a
continuous intravenous infusion over 60 min. The ﬁrst infusion of the
extension study was 2 weeks after the last infusion of the parent trial
(no break in treatment).
In the parent trial, patients received the same ERT infusion dose
between 15 and 60 U/kg as received when they were being treated
with imiglucerase. In the extension study, each patient continued to re-
ceive the same dose unless a dose increase was clinically indicated (due
to signiﬁcant worsening in important variables, i.e., hemoglobin
concentration, platelet count, liver volume and spleen volume).
Patients received 26 doses of velaglucerase alfa in the parent trial
(approximately 12months). Theywere to be treatedwith velaglucerase
alfa EOW in the extension study until the drug became commercially
available to them. The efﬁcacy endpoints of the extension study were
determined from data at 24 months from the baseline of the parent
trial, i.e., at 12 months in the extension study.
2.4. Safety assessments
Patients were monitored for adverse events (AEs) throughout the
studies, including worsening of conditions present at the start of the
study, clinically signiﬁcant abnormalities in laboratory values, and
events related to concomitant medications. The investigators assessed
the severity of AEs and causality (whether an AE was related to treat-
mentwith the study drug). Other safety assessments includedmeasure-
ment of vital signs before, during, and after infusions and regular clinical
laboratory tests, electrocardiography, physical and neurological exami-
nations, weight measurements, and urine pregnancy testing. Serum
samples were screened for anti-velaglucerase alfa antibodies using an
electrochemiluminescent bridging assay approximately every 12
weeks. Samples which were above the cut point in the screening assay
were then tested in a drug competition assay. Any samples which
were above the cut point in the competition assay were deemed
positive for anti-drug antibodies.
2.5. Efﬁcacy assessments
Blood was sampled every 6 weeks in the parent trial and every
12 weeks in the extension study to measure hemoglobin concentration
and platelet count at a central laboratory. The biomarkers chitotriosidase
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weeks. Plasma chitotriosidase activity was measured with an enzymatic
assay using 4-methylumbelliferyl-deoxychitobiose as a substrate and
plasma CCL18 level was measured using a time-resolved ﬂuorescence
assay (Academic Medical Center, Amsterdam, The Netherlands).
Abdominal magnetic resonance imaging (MRI) was employed to
measure liver and spleen volumes; scans were obtained at week 25
(week 25 from the baseline of the parent trial), week 51 (start of exten-
sion study), and week 103, and assessed centrally by a radiologist
blinded to patients' identities. Organ volumes were normalized to
body weight (expressed as a percentage of body weight). The volumes
were also expressed asmultiples of normal,with onemultiple of normal
for the liver and spleen corresponding to 2.5% body weight and 0.2%
body weight, respectively.
MRI images of the lumbar spine and femurs taken at weeks 25, 51,
77, 103 and 129 (every 6 months) were evaluated by a central radiolo-
gist blinded to patient identity and image sequence, who determined
BMB scores using the method of Maas and colleagues [16].
In pediatric patients (b18 years of age at baseline, i.e., at entry into
the parent trial), height measurements (cm) were converted to height
percentiles and height Z-scores based on the patient's sex and age (in
months) and World Health Organization 2007 growth reference data.
Annualized growth velocity (cm/year) was also calculated from serial
height measurements. Bone age was determined from plain radio-
graphs of the left hand andwrist taken every 6months. The radiographs
were interpreted by a single radiologist without knowledge of the
patient's chronological age [17] and bone ages (in years) were convert-
ed to bone age Z-scores using reference sex-speciﬁc X-ray plates from
the Brush Foundation Study.
In adult patients, BMD in three anatomical regions (lumbar spine,
femurs, and femoral necks) was measured every 6 months using dual
energy X-ray absorptiometry (DXA). A blinded analysis of the DXA
data was conducted at the BioMedical Imaging Laboratory (Wright
State University, Dayton, OH, USA). BMD measurements (in g/cm2)
were converted to BMD Z-scores using age- and sex-matched reference
values from the Hologic, Inc. database, and also converted to BMD T-
scores (a person's BMD expressed as the number of standard deviations
above or below the average for a young adult at peak BMD). Blood was
also assayed for serum levels of bone loss and demineralization
markers, every 6months in the extension study, at a central laboratory:
bone-speciﬁc alkaline phosphatase (BSAP) using an enzyme-linked im-
munosorbent assay (ELISA), type I collagen telopeptides N-terminal
cross-links (NTx) using ELISA, and type I collagen telopeptides C-
terminal cross-links (CTx) with Elecsys.Table 1
Characteristics of each patient at baseline (start of parent trial).
Patients b18 years of age
Patient 1 2
Age 11 years 14 years
Sex M M
GD clinical subtype Type 1 GD Type 3 GD
Neurological status Abnormal
(hypoacusia)
Abnormal (abnormal ey
movement)
Imiglucerase therapy prior to parent trial
Duration 9.9 years 8.9 years
Dose 48.9 U/kg 56.9 U/kg
Chitotriosidase gene 24-base pair
duplication?
One allele One allele
Serum anti-velaglucerase alfa antibodies Negative Negative
Hemoglobin concentration, g/dL 12.4 14.4
Platelet count ×109/L 202 147
Normalized liver volume, MN 1.01 0.64
Normalized spleen volume, MN 2.40 1.55
Plasma chitotriosidase activity,
nmol/mL/h
– –
Plasma CCL18 level, ng/mL 382 52
MN, multiples of normal.2.6. Statistical analysis
All enrolled patients who received at least one product infusion in
the extension study were included in this analysis. Within-patient
changes in efﬁcacy variables between baseline and week 101 or 103 of
treatment (24 months) were summarized with descriptive statistics.
No formal statistical tests were performed due to the small sample
size. The statistical analysis was performed using SAS® software version
9.3.
Chitotriosidase activity was not evaluated in any patients who were
deﬁcient in this enzyme due to a 24-base pair duplication in either copy
of their chitotriosidase gene.
3. Results
3.1. Disposition and dosing
Six patients completed the parent trial and ﬁve patients were en-
rolled into and completed the extension study (Table 1); one patient
did not enroll into the extension study for personal reasons. Two of
three pediatric patients enrolled had type 3 GD; the other pediatric pa-
tient and both adult patients had type 1 GD. In these ﬁve patients, the
number of infusions received in the extension study ranged from 30
to 40, and the duration of study participation ranged from 63 to
78 weeks (total study period including the parent trial was 116–130
weeks). The average dose received during the extension study ranged
from 51.5 to 60.7 U/kg. One patient (Patient 1) had their dose increased
from 48.7 to 60.0 U/kg at week 103 due to worsening auditory distur-
bance that was considered by the investigator to represent worsening
GD; because this was not a protocol-speciﬁed criterion for dose
increase, the dose adjustment was recorded as a protocol deviation.
All ﬁve patients used concomitant medication during the study;
however, no patient received erythropoietin, premedication to prevent
infusion reactions or iron supplements. One adult patient received
alendronic acid for bone disease.
3.2. Safety in the extension study
Headache was the most common AE (experienced by three
patients). Nasopharyngitis, gastroenteritis, upper abdominal pain,
hordeolum, contusion, and excoriation were experienced by two
patients each.
Two patients experienced serious AEs (SAEs; Table 2): two SAEs of
retinal detachment and two SAEs of vitreous opacities in one patientPatients ≥18 years of age
3 4 5
15 years 26 years 39 years
M M F
Type 3 GD Type 1 GD Type 1 GD
e Abnormal (abnormal eye movement and
dysmetria)
Normal Normal
12.5 years 13.6 years 14.2 years
60.0 U/kg 60.0 U/kg 60.0 U/kg
Both alleles No No
Negative Negative Negative
14.4 14.4 12.6
180 183 162
0.77 0.74 0.64
2.25 1.65 1.85
– 942 1170
187 74 35
Table 2
Summary of treatment-emergent AEs (extension study safety population, N = 5).
Extension study Parent trial and extension study
Patients experiencing event, n Events total Patients experiencing event, n Events total
At least one AE 5 64 5 104
Mild or moderate 3 59 3 99
Severe 2 5a 2 5
At least one SAE 2 6a 2 7
At least one study drug related AEb 2 3c 3 8
Severe and study drug related AE 1 1 1 1
SAE and study drug related 0 1 1
At least one infusion reactiond 0 1 2
Discontinued study due to an AE 0 0
a Severe AEs: increased blood creatine phosphokinase and four AEs of hypoacusis; SAEs: listed in main text; severe and serious are not mutually exclusive categories: all events were
graded according to their severity, i.e., intensity (mild, moderate, severe) and any events that met certain outcome or action criteria associated with a threat to life or functioning were
considered to be serious.
b Related = possibly related, probably related or deﬁnitely related. All three study drug related AEs in the extension study were reported as “possibly” related.
c One of the three AEs was subsequently considered possibly related to physical exercise.
d Infusion reaction = any AE starting within 12 h of the start of the infusion (close temporal relationship with infusion) and judged to be possibly, probably or deﬁnitely related to the
study drug.
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another patient (Patient 1). None of the SAEs were considered related
to treatment.
A total of three (non-serious) events in two patients were reported as
possibly related to velaglucerase alfa: upper abdominal pain, alopecia and
increased blood creatine phosphokinase. The increased blood creatine
phosphokinase was subsequently noted by the investigator as possibly
being related to physical exercise and not to velaglucerase alfa treatment.
No signiﬁcant changes over time were apparent in clinical
chemistry, hematology, and urinalysis results. All electrocardiography
parameters were stable; none of the patients tested positive for anti-
velaglucerase alfa antibodies and patients with neurologicalFig. 1.Observedvalues in individual patients and themeansover 24months. (A)Hemoglobin co
standard deviation.abnormalities at baseline (Table 1) had the same abnormalities after
24 months of treatment.
3.3. Efﬁcacy results
Over 24 months, hemoglobin levels and platelet counts were gener-
ally maintained and normalized liver and spleen volumes remained
stable (Fig. 1). All patients maintained a hemoglobin concentration
N10 g/dL and a platelet count N100 × 109/L at each time point.
Three of ﬁve patients had a 24-base pair duplication in one or both
copies of the chitotriosidase gene (Table 1), so they were excluded
from the chitotriosidase analysis. In the other two patients, one had anncentration; (B) platelets; (C) normalized liver volume; (D) normalized spleen volume. SD,
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months and the other patient's chitotriosidase activity was stable
(decrease of 0.8%). Plasma CCL18 concentrations ranged from 35 to
382 ng/mL at baseline, and from 39 to 280 ng/mL at 24 months, with
no apparent trend in values over the study period (Fig. 2).
In the three pediatric patients, patients 1, 2, and 3, height Z-scores
changed by 0.4, −0.4, and −0.7, respectively, from baseline to 24
months. Over 24 months, patient 1 grew by approximately 20 cm
(annualized growth velocity ranging from 4.5 to 8.2 cm/year); the
patient was in the 14.4th height percentile at baseline and the 24.4th
percentile at 24 months. Patient 2 grew 4.5 cm (annualized growth
velocity ranging from 1.9 to 3.4 cm/year); this patient was in the
54.0th height percentile at baseline and the 38.0th percentile at 24
months. Patient 3 remained at approximately the same height, going
from the 10.1st height percentile at baseline to the 2.5th at 24 months.
One of the pediatric patients (patient 1) had an abnormally lowbone
age at baseline (Z-score−5.5), which improved to approach his chro-
nological age at 24months (Z-score−0.9). For a bone age to be consid-
erednormal, it should liewithin two standard deviations of the patient's
chronological age, i.e., a bone age Z-score no greater than 2 and no less
than−2 [18]. For the other two pediatric patients, bone age Z-scores
changed frombetween−0.1 and 1.3 at baseline to 0.9 (in bothpatients)
at 24 months.
Total BMB scores in the pediatric patients ﬂuctuated between time
points. One patient (patient 1) had a clinically remarkable decrease
(improvement) in his total score at both 18 and 24 months, i.e., ≥4
points [19]; although at 18months, the changewas−9 points, whereas
at 24 months, the change was −4 points (all in the lumbar spine),
compared with a total score of 10 at baseline. One pediatric patient's
total BMB score (patient 2) was 2 points greater at 24 months than at
baseline. The third pediatric patient had a clinically remarkable
improvement in his total score at 18 months (−5 points), but not at
24 months (−3 points).
Total BMB scores of the adult patientswere not signiﬁcantly changed
during the study and BMD Z-scores were essentially unchanged over 24
months (Table 3). The 26-year-old male patient did not receive
concomitant medication for bone disease and had a medical history of
right hip joint pain at baseline. The 39-year-old female patient received
concomitant bisphosphonates and had a medical history of osteopenia.
There were no clinically meaningful changes in BSAP, NTx, and CTx
concentrations; changes from baseline were−11.5 and−5.5 U/L for
BSAP, −5.6 and −0.4 nM bone collagen equivalents for NTx, and
0.057 and 0.087 ng/mL for CTx.Fig. 2. Observed values in individual patients and the means over 24 months. (A) Plasma
chitotriosidase activity; (B) plasma CCL18 level (mean at 51 weeks is based on values for
n = 4). SD, standard deviation.4. Discussion
The safety, tolerability, efﬁcacy and immunogenicity of vela-
glucerase alfa in Japanese patients with GD in this 12-month extension
study was consistent with that in the 12-month parent trial and that
previously observed in non-Japanese patients switching from imigluce-
rase [5,11]. In the extension study, only three of 64 AEswere reported as
related to the study drug, none of which were SAEs and one of which
was possibly linked to physical exercise rather than the study drug; no
AEs led to study discontinuation, clinical efﬁcacy variables were gener-
ally maintained, and no patient tested positive for anti-velaglucerase
alfa antibodies.
The patient who experienced two SAEs of hypoacusis during the ex-
tension study had a history of worsening deafness before velaglucerase
alfa treatment was started; the SAEs of hypoacusis were most likely
related to progression of the underlying disease, probably involving
peripheral neuropathy, which is a potential complication of GD [20].
The two SAEs of vitreous opacities and two SAEs of retinal detachment
were considered to be complications of GD; ocular manifestations in
patients with GD, including vitreous abnormalities, have been reported
in the literature [21].CCL18 and chitotriosidase are secreted by Gaucher cells and are
markers for disease burden; consequently, plasma levels of these bio-
markers are signiﬁcantly increased in untreated patients with GD [22,
23]. Interestingly, the mean plasma chitotriosidase activity decreased
by 34% and the mean CCL18 level decreased by 51% over 24 months in
the larger, international trial of velaglucerase alfa conducted in patients
switching from imiglucerase and its extension study [11,13]. There was
also an overall downward trend in spleen volumes and upward trend in
platelet counts that were not seen in the current study, possibly due to
the small number of patients. In the current study, except for a 39%
decrease in plasma chitotriosidase activity in the 26-year-old male
patient, plasma biomarker levels were generally stable over 24months.
Yet the results of this small study are consistent with a sustained
response to ERT.
Clinically signiﬁcant changes were observed in the 11-year-old pa-
tient, whose total BMB scorewas 4 points lower at 24months compared
with baseline. BMB scores range from 0, indicating no abnormality, to 8,
indicating severe marrow inﬁltration by Gaucher cells, and the scoring
system is based onmanual interpretation ofMRI images [16]. In a recent
report by Jaramillo and colleagues, there was no statistically signiﬁcant
difference in BMB scores between treated pediatric patients with type 1
GD and healthy age-matched control subjects, although the fat fraction
in the femurs quantiﬁed using protonmagnetic resonance spectroscopy
was higher in control subjects (where the degree of marrow inﬁltration
is inversely correlated with the fat fraction) [24]. All these observations
notwithstanding, due to the normal presence of red bone marrow in
children, the interpretation and clinical relevance of BMB scoring or
fat fraction in children is less clear than in adults and warrants further
investigation [25].
The bone age of the 11-year-old patient also improvedmarkedly over
the 2-year study period. The bone age at baseline was over 5.5 standard
Table 3
Observed values for efﬁcacy variables and GD biomarkers at yearly intervals, and change over time.
Median change or % change from baseline
to 24 mo (range)
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Baseline 12 mo 24 mo Baseline 12 mo 24 mo Baseline 12 mo 24 mo Baseline 12 mo 24 mo Baseline 12 mo 24 mo
Hemoglobin, g/dL −0.10 (−0.4, 1.6) 12.4 12.6 14.1 14.4 13.7 14.1 14.4 15.3 14.8 14.4 15.5 14.1 12.6 11.9 12.5
Platelet count ×109/L 5.0 (0, 32) 202 187 231 147 202 158 180 247 183 183 169 175 162 149 161
Normalized liver volume, MN −2.29% (−10.3%, 18.8%) 1.01 1.00 0.90 0.64 0.65 0.76 0.77 0.89 0.75 0.74 0.79 0.72 0.64 0.60 0.68
Normalized spleen volume, MN 3.04% (−11.8%, 43.5%) 2.40 2.45 2.12 1.55 1.60 1.57 2.25 2.75 2.72 1.65 1.45 1.57 1.85 2.35 2.64
Plasma chitotriosidase activity,a nmol/mL/h – – – – – – – – – 942 886 571 1170 1191 1179
Plasma CCL18 level, ng/mL 8 (−102, 19) 382 383 280 52 65 60 187 192 206 74 91 88 35 NA 39
BMB scores
Lumbar 0 (−4, 0) 7 7 3 1 1 1 3 1 1 1 1 1 1 1 1
Femoral 0 (−3, 2) 3 3 3 0 3 2 3 2 2 0 0 2 5 NA 2
Total −3 (−4, 2) 10 10 6 1 4 3 6 3 3 1 1 3 6 NA 3
Pediatric patients only
Height Z-score −0.4 (−0.7, 0.4) −1.1 −1.3 −0.7 0.1 −0.0 −0.3 −1.3 −1.7 −2.0
Bone age Z-score 0.9 (−0.4, 4.6) −5.5 −0.5 −0.9 −0.1 1.8 0.9 1.3 1.6 0.9
Adult patients only
BMD Z-scores
Lumbar −1.4 −1.4 −1.4 0.3 −0.2 0.2
Femoral −0.4 −0.4 −0.3 −1.0 −0.9 −0.9
Femoral neck −0.5 −0.5 −0.7 −1.0 −0.9 −0.8
BMD T-scores
Lumbar −1.4 −1.4 −1.4 0.1 −0.0 0.0
Femoral −0.4 −0.4 −0.3 −1.2 −1.1 −1.0
Femoral neck −0.5 −0.5 −0.7 −1.4 −1.3 −1.2
Bone markers
CTx, ng/mL 0.129 0.200 0.186 0.054 0.152 0.141
NTx, nM BCE 9.5 11.1 9.1 11.8 7.5 6.2
BSAP, U/L 33.5 30.4 22.0 20.5 22.1 15.0
mo, months; MN, multiples of normal; NA, not available; BCE, bone collagen equivalents.
a Individual plasma chitotriosidase values shown only for the two patients with wild type chitotriosidase alleles.
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10 years before study entry; data from a large disease-speciﬁc registry
suggest that bone parameters in children improve signiﬁcantly and
height Z-scores can normalizewithin 8 years of initiating ERT [26]. How-
ever, the mechanisms of change in bone involvement are not clear and
further studies could be required to elucidate this issue. Even if these
pediatric data are more in the form of case observations, they are in
line with and support observations in earlier clinical trials of a positive
effect of velaglucerase alfa treatment on growth in children [15].
Velaglucerase alfa treatment had no apparent effect on the neuro-
logical abnormalities observed in the two patients with type 3 GD, but
we would not have expected it because there is no known effective
therapy for neurological features of GD; this remains a signiﬁcant
unmet treatment need.
The main limitation of this study is the small sample size, due to the
rarity of GD. However, the concordance of these results with a larger
switch trial (n = 40) conducted in a previous, international study
suggests that velaglucerase alfa treatment is similarly well tolerated
and effective in Japanese patients with GD switching from imiglucerase
therapy [11].
5. Conclusion
The results of this 12-month extension study evaluating EOW
administration of velaglucerase alfa in Japanese patients with GD
support the safety and efﬁcacy of its use over a 24-month period.
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